U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  FORM 10-K (Amendment #1) (Mark One)  [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the fiscal year ended December 31, 2018  [   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  for the transition period from ___________ to _____________  Commission File Number: 000-54296  AXIM.jpg  AXIM Biotechnologies, Inc. (Exact name of registrant as specified in its charter)  Nevada27-4029386(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)  45 Rockefeller Plaza, 20th Floor, Suite 83 New York, NY 10111 (Address of principal executive offices)  Registrant’s telephone number, including area code: (212) 332-1677  Securities registered pursuant to Section 12(b) of the Act: None  Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value  Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [   ] No [X]  Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [   ] No [X]  Note – Checking in the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act form their obligations under those Sections.  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [   ]  Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [   ]       Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K. [X]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act.  Large accelerated filer[   ]Accelerated filer[   ]Non-accelerated filer[   ] Do not check if smaller reporting company)Smaller reporting company[X]Emerging growth Company[   ]  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.[   ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ] No [X]  The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant as of June 30, 2018, based upon the closing price of the common stock as reported by finance.yahoo.com on such date, was approximately $30,369,429. This calculation does not reflect a determination that persons are affiliates for any other purposes.  As of April 8, 2019, there were 61,072,411 shares of the registrant’s common stock were issued and outstanding.  DOCUMENTS INCORPORATED BY REFERENCE:None  EXPLANATORY NOTE  This Amendment No. 1 to Form 10-K (“Amendment No. 1”) amends the Annual Report of AXIM Biotechnologies, Inc. (the “Company”) on Form 10-K for the Fiscal Year ended December 31, 2018, as filed with the Securities and Exchange Commission on April 8, 2019 (the “Original Filing”). This Amendment No. 1 is being filed for the sole purpose of furnishing Exhibits 10.4, 10.5, 10.6 and 10.7.  No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks as of the original filing date of the Form 10-K does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original Filing.     Exhibit Index  Incorporated by Reference
(Form Type)Filed
with
This
ReportExhibitsExhibit #Filing DateArticles of Incorporation, as filed with the Nevada Secretary of State on November 18, 2010.3.110-Q11/14/2014Certificate of Amendment, as filed with the Nevada Secretary of State on July 24, 2014.3.210-Q11/14/2014Amended and Restated (As of August 17, 2016) Bylaws of AXIM Biotechnologies, Inc.3.310-Q8/22/2016Certificate of Designation of Series B Preferred Stock.3.410-Q8/22/2016Certificate of Designation of Series C Preferred Stock.3.510-Q8/22/2016Amended and Restated Employment Agreement effective September 1, 2016, by and between AXIM International, Inc. and Dr. George E. Anastassov.10.110-Q11/21/2016Amended and Restated Employment Agreement effective September 1, 2016, by and between AXIM International, Inc. and Lekhram Changoer.10.210Q11/21/2016Employment Agreement effective September 1, 2016, by and between AXIM International, Inc. and Dr. Philip A. Van Damme.10.310-Q11/21/2016Letter of Intent (“Terms Sheet”) dated September 3, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc.10.4XExclusivity Agreement dated September 3, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc.10.5XAmendment #1 to Exclusivity Agreement dated December 11, 2018, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc.10.6XSupply Agreement dated May 31, 2019, by and between Impression Healthcare Limited and AXIM Biotechnologies, Inc.10.7XCode of Business Conduct and Ethics.14.110-Q11/20/2017Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.1XConsent of Independent Registered Public Accounting Firm23.1XCertification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2XCertification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.1*XCertification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2*XNominating and Governance Committee Charter.99.110-Q11/20/2017     Compensation Committee Charter.99.210-Q11/20/2017Audit Committee Charter.99.310-Q11/20/2017XBRL Instance Document101.INSXXBRL Taxonomy Extension Schema Document101.SCHXXBRL Taxonomy Extension Calculation Linkbase Document101.CALXXBRL Taxonomy Extension Definition Linkbase Document101.DEFXXBRL Taxonomy Extension Label Linkbase Document101.LABXXBRL Taxonomy Extension Presentation Linkbase Document101.PREX   F-2     *These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing  SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  SignatureTitleDate/s/ John W. Huemoeller IIPresident and Director (Principal Executive Officer)October 29, 2019John W. Huemoeller II/s/ Robert MalasekChief Financial Officer (Principal Financial Officer)October 29, 2019Robert Malasek/s/ Lekhram ChangoerDirectorOctober 29, 2019Lekhram Changoer/s/ Dr. George AnastassovDirectorOctober 29, 2019Dr. George Anastassov/s/ Timothy R. Scott, PhDDirectorOctober 29, 2019Timothy R. Scott, PhD/s/ Robert CunninghamDirectorOctober 29, 2019Robert Cunningham/s/ Dr. Philip A. Van DammeDirectorOctober 29, 2019Dr. Philip A. Van Damme/s/ Mauricio Javier Gatto-BelloraDirectorOctober 29, 2019Mauricio Javier Gatto-Bellora   F-3